Patients treated with enfortumab vedotin for advanced urothelial carcinoma (aUC), who had baseline neuropathy or diabetes mellitus “did not appear to have inferior outcomes,” according to an analysis of the multi-site, retrospective UNITE study. The researchers evaluated the efficacy of enfortumab vedotin, both in combination with pembrolizumab and as a monotherapy, for patients with neuropathy or diabetes mellitus, as many patients with those comorbidities were not included in landmark trials of enfortumab vedotin. The researchers hypothesized that no significant difference would be found ...
Advertisement
Latest News
Before axatilimab, targeting the CSF-1R pathway was not previously studied in cGVHD.
New research and therapeutic approaches are challenging long-held beliefs about this type of graft.
Lisa Hwa, APRN, CNP, DNP, MS, said the comprehensive fellowships will help prepare APPs working in complex specialties.
As a nonpharmacological intervention with high acceptability and enjoyment, virtual reality may be an effective strategy.
In addition to knowing what herbal products patients take, it’s equally as important to understand why they take them.
Understanding critical symptoms in the “CRAB” acronym can enable oncology nurses to educate patients and caregivers.
Up to 50% of patients have renal insufficiency at the time of multiple myeloma diagnosis.
The FDA also approved the VENTANA CLDN18 RxDx Assay as a companion diagnostic device.
Kohei Shitara, MD, unpacks the SPOTLIGHT and GLOW data behind the approval.
The program, titled “Nurse Well-Being: Building Peer and Leadership Support,” is based on the Stress First Aid model.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, discusses her experiences and shares resources.
Learn how a team developed a predictive model for breast cancer using cfDNA low-pass whole genome sequencing.
Advertisement
Advertisement
Our Contributors
Theresa Brown, RNTheresa Brown, RN, is the New York Times best-selling author of "Healing" and "The Shift."
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®, is the owner of beyond Oncology Education, LLC.
Milagros Elia, MA, APRN, ANP-BCMilagros R. Elia, MA, APRN, ANP-BC, has 25+ years of oncology experience and is a highly regarded activist.
Pamela K. Ginex, EdD, MPH, RN, OCNPamela K. Ginex, EdD, MPH, RN, OCN, is an Assistant Professor at the Stony Brook University School of Nursing.
Teresa Hagan Thomas, PhD, RNTeresa Hagan Thomas, PhD, RN, is an Assistant Professor at the University of Pittsburgh School of Nursing.
Amanda Brink, DNP, APRN, FNP-BC, AOCNPAmanda Brink, DNP, APRN, FNP-BC, AOCNP, is an oncology nurse practitioner at the MD Anderson Cancer Center.
Alicia Michaelsen, BSN, RN, BMTCN®Alicia Michaelsen, BSN, RN, BMTCN®, is a nurse with over a decade of experience.
Fatemeh Youssefi, PhD, RN, OCNFatemeh Youssefi, PhD, RN, OCN, is a nurse who has specialized in oncology for the past 20 years.
Expert Interviews
Cancer Nursing Today delivers critical news and expert insights to support oncology nurses throughout their education and careers.
Sign up to receive Cancer Nursing Today eNewsletters:
Conference Highlights
Lisa Hwa, APRN, CNP, DNP, MS, said the comprehensive fellowships will help prepare APPs working in complex specialties.
Learn how a team developed a predictive model for breast cancer using cfDNA low-pass whole genome sequencing.
The study analyzed quality-adjusted time without symptoms of disease progression or toxicity of treatment, known as Q-TWiST.
Patients who received the vaccine within 100 days of starting an immune checkpoint inhibitor showed improved survival.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.